Observational studySleep medicine2026
Positive airway pressure therapy and cardiovascular events in obstructive sleep apnoea: an observational clinical cohort study.
Observational study in Sleep medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-term effect of continuous positive airway pressure on cardiovascular outcomes after acute myocardial infarction in obstructive sleep apnea patients.Sleep & breathing = Schlaf & Atmung · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
aimsStudies support the short-term benefit of continuous positive airway pressure (CPAP) therapy on cardiometabolic risk in adults with obstructive sleep apnoea (OSA). Evidence is limited on the benefits of CPAP for preventing acute major adverse cardiovascular events (MACE). This study aimed to assess the association between CPAP use and incidence of MACE in a longitudinal clinical cohort of adults with OSA at a large U.S. healthcare system.
methodsAdults with OSA (apnoea-hypopnoea index [AHI]≥5) were identified from Kaiser Permanente Southern California between 2018 and 2020 (N = 34,782). MACE was defined as first occurrence of myocardial infarction, stroke, unstable angina, heart failure or cardiovascular death, using validated electronic health record algorithms. CPAP use (h/night) was based on daily telemonitoring data. Inverse probability of treatment weighted Cox proportional hazards models stratified by OSA severity (mild [5≤AHI<15]), moderate-severe [AHI ≥15]), were used to assess associations between CPAP use and MACE.
resultsAmong individuals with moderate-severe OSA, those using CPAP <4 h/night (HR [95 % CI] = 0.53 [0.35-0.82]; p = 0.004) or ≥4 h/night (HR [95 % CI] = 0.46 [0.27-0.77]; p = 0.004) had lower MACE incidence compared to those not using CPAP. Increased CPAP use (in hours) was associated with lower MACE incidence in moderate-severe OSA (HR [95 % CI] = 0.90 [0.82-0.98]; p = 0.021). In individuals with mild OSA, CPAP use was not associated with lower MACE incidence.
conclusionCPAP use was associated with lower MACE incidence in adults with moderate-severe OSA. Treatment of moderate-severe OSA may have a positive impact on prevention of MACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.